In March 2026, Codexis reported that Q4 2025 revenue rose to US$38.92 million with net income of US$9.6 million, while full-year revenue reached US$70.39 million alongside a reduced net loss and new ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting primary and secondary endpoints with strong efficacy and safety. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results